Fatigue syndromes

1 paper1 finding

Interventions

1

Intravenous longevity therapy

downin reviews1

1 study

Intravenous longevity therapy decreases fatigue syndromes.
“modest improvements in fatigue syndromes”
Reviewfatigue syndromes
Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility
Acta dermatovenerologica Alpina, Pannonica, et Adriatica1 Mar 2026

More on Intravenous longevity therapy

Latest

3 in 12 months

Acta Dermatovenerologica Alpina, Pannonica, et Adriatica31 Mar

Intravenous longevity therapy: a critical review of evidence, mechanisms, and clinical utility

ReviewInterventions

Comprehensive Physiology13 Jan

Immunosenescence-Driven Hemodynamic Dysregulation and Cognitive Impairment in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Integrative Perspective

ReviewMechanisms

Cell Death & Disease10 Jan

Virus-induced endothelial senescence as a cause and driving factor for ME/CFS and long COVID: mediated by a dysfunctional immune system

ReviewImmune response

Reviews in Endocrine & Metabolic Disorders23 Oct

Metabolic reprogramming in diabetes and other endocrine and metabolic disorders: exploring the Warburg effect, ketones, and SGLT2 inhibitors

ReviewSGLT2 inhibitors

Comprehensive Physiology29 Sep

Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Physical Fatigue Through the Perspective of Immunosenescence

ReviewMechanisms

Hormone and Metabolic Research12 Sep

Single-Center Study of Therapeutic Apheresis in 24 Male Patients from the MENA Region: Reduction of Lipids, Inflammatory Markers, Autoantibodies, and Implications for Fatigue, Genetics, and Aging

Non-randomised trial in 24 peopleInterventions

Experimental Gerontology14 Aug

Epstein-Barr virus and the origin of frailty and fatigue: A two-sample multivariable bidirectional Mendelian randomization study

Study in peoplePopulations

The Lancet Public Health14 Jun

Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants

Cohort study of 493,737 peopleMultimorbidity